Pacira BioSciences, Inc. $PCRX Stock Holdings Increased by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd lifted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 51.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,575 shares of the company’s stock after purchasing an additional 4,612 shares during the quarter. Persistent Asset Partners Ltd’s holdings in Pacira BioSciences were worth $324,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in Pacira BioSciences in the 1st quarter valued at about $51,000. Brooklyn Investment Group raised its position in shares of Pacira BioSciences by 372.2% during the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock worth $56,000 after buying an additional 1,764 shares in the last quarter. US Bancorp DE lifted its stake in shares of Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after acquiring an additional 537 shares during the period. Wealthquest Corp bought a new position in shares of Pacira BioSciences in the first quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new position in shares of Pacira BioSciences during the first quarter valued at approximately $75,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PCRX shares. Truist Financial cut their target price on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Wall Street Zen upgraded Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pacira BioSciences in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average target price of $33.00.

Pacira BioSciences Trading Up 0.7%

Shares of NASDAQ PCRX opened at $23.78 on Friday. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. Pacira BioSciences, Inc. has a 12 month low of $16.00 and a 12 month high of $27.64. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -8.55 and a beta of 0.36. The business has a fifty day simple moving average of $23.93 and a 200-day simple moving average of $24.36.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company had revenue of $179.52 million during the quarter, compared to analyst estimates of $182.86 million. During the same period in the prior year, the firm earned $0.79 earnings per share. The business’s quarterly revenue was up 6.5% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. Sell-side analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.